Can Pacific Biosciences of California Inc. (PACB) Add Value To Your Portfolio?

As of Thursday close, Pacific Biosciences of California Inc.’s (NASDAQ:PACB) stock was up $0.6, moving up 11.52 percent to $5.81. The average number of shares traded per day over the past five days has been 7,671,140 shares. 5 times new highs have been achieved over the past 5 days, with a $1.32 gain in that time frame. In the last twenty days, the average volume was 6,032,260, while in the previous 50 days, it was 6,633,930.

Since last month, PACB stock rose 12.82%. Shares of the company fell to $3.89 on 07/18/22, the lowest level in the past month. A 52-week high of $35.58 was reached on 01/04/22 after having rallying from a 52-week low of $3.85. Since the beginning of this year, PACB’s stock price has dropped by -71.60% or -$14.65, and marked a new high 2 times. However, the stock has declined by -83.67% since its 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Pacific Biosciences of California Inc. (PACB) last reported insider trading activity 79 days ago on May 18. Farmer Michele, the See Remarks of the company, disposed of 3,573 shares for $5.55 on May 18. It resulted in a $19,819 divestment by the insider. Kim Susan G. sold 1,062 shares at an average price of $11.06 on Feb 17. The insider now owns 134,966 shares following the transaction. On Feb 17, President & CEO HENRY CHRISTIAN O sold 2,122 shares at $11.09 apiece. The transaction was valued at $23,533.

Valuation Metrics

The stock’s beta is 1.46. Besides these, the trailing price-to-sales (P/S) ratio of 9.94, the price-to-book (PB) ratio of 1.76.

Financial Health

In the three months ended June 29, Pacific Biosciences of California Inc.’s quick ratio stood at 16.40, while its current ratio was 16.90, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 1.22, and the total debt-to-equity ratio was 1.22. On the profitability front, the trailing twelve-month gross margin is 44.60% percent. Based on annual data, PACB earned $58.86 million in gross profit and brought in $130.51 million in revenue.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. PACB’s revenue rose 12.57% to $35.9 million during the quarter, while net income inched up to $33.17 million. While analysts expected Pacific Biosciences of California Inc. to report -$0.32 quarterly earnings, the actual figure was -$0.32 per share. During the quarter, the company generated -$72.41 million in EBITDA. The liabilities of Pacific Biosciences of California Inc. were 1.2 billion at the end of its most recent quarter ended June 29, and its total debt was $950.22 million. The value of shareholders’ equity is $224.38 million.

Technical Picture

This quick technical analysis looks at Pacific Biosciences of California Inc.’s (PACB) price momentum. With a historical volatility rate of 72.60%, the RSI 9-day stood at 73.06% on 04 August.

With respect to its five-day moving average, the current Pacific Biosciences of California Inc. price is up by +29.40% percent or $1.32. At present, PACB shares trade +3.75% above its 20-day simple moving average and -41.31% percent below its 100-day simple moving average. However, the stock is currently trading approximately +1.22% above its SMA50 and -76.08% below its SMA200.

Stochastic coefficient K was 82.91% and Stochastic coefficient D was 68.89%, while ATR was 0.60. Given the Stochastic reading of 77.42% for the 14-day period, the RSI (14) reading has been calculated as 64.06%. As of today, the MACD Oscillator reading stands at 0.59, while the 14-day reading stands at 0.70.

Analyst Ratings

Pacific Biosciences of California Inc. (PACB) has been rated Overweight by analysts. According to 0 brokerage firms, PACB is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Pacific Biosciences of California Inc. stock as buy, with 3 recommending it as overweight.

With a median target price of $12.00, the current consensus forecast for the stock is $6.00 – $19.00. Based on these forecasts, analysts predict Pacific Biosciences of California Inc. (PACB) will achieve an average price target of $11.83.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles